A multi-center evaluation of TECHNOSCREEN(R) ADAMTS-13 activity assay as a screening tool for detecting deficiency of ADAMTS-13

被引:26
作者
Moore, Gary W. [1 ,2 ]
Meijer, Danielle [3 ]
Griffiths, Margaret [4 ]
Rushen, Lucy [1 ]
Brown, Alice [1 ]
Budde, Ulrich [5 ]
Dittmer, Rita [5 ]
Schocke, Barbara [5 ]
Leyte, Anja [3 ,6 ]
Geiter, Sabine [4 ]
Moes, Anneke [3 ]
Cutler, Jacqueline A. [1 ]
Binder, Nikolaus B. [4 ]
机构
[1] Guys & St Thomas Hosp, Diagnost Haemostasis & Thrombosis, Viapath Analyt, London, England
[2] Addenbrookes Hosp, Specialist Haemostasis Unit, Cambridge, England
[3] Sanquin Diagnost BV, Immune Pathol & Haemostasis Labs, Amsterdam, Netherlands
[4] Technoclone GmbH, Vienna, Austria
[5] MEDILYS Laborgesellschaft mbH, Dept Hemostaseol, Hamburg, Germany
[6] OLVG Lab BV, Amsterdam, Netherlands
关键词
ADAMTS-13; activity; screening test; thrombotic microangiopathy; thrombotic thrombocytopenic purpura; THROMBOTIC THROMBOCYTOPENIC PURPURA; VON-WILLEBRAND-FACTOR; FACTOR-CLEAVING PROTEASE; DIAGNOSIS; MICROANGIOPATHIES; VALIDATION; INHIBITOR; REGISTRY; TTP;
D O I
10.1111/jth.14815
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Quantifying A disintegrin-like and metalloprotease with thrombospondin type 1 motif, member 13 (ADAMTS-13) activity enhances thrombotic thrombocytopenic purpura (TTP) diagnosis but most assays are time consuming, technically demanding, and mainly available in reference centers. Objective Evaluate a simple, semiquantitative ADAMTS-13 activity screening test for early identification/exclusion of TTP. Patients/Methods Plasma from 220 patients with suspected thrombotic microangiopathy at three reference centers were tested with TECHNOSCREEN(R) ADAMTS13 activity screening test in comparison with TECHNOZYM(R) ADAMTS-13 activity ELISA at two centers, and in-house fluorescence resonance energy transfer assay at the third center. The screening test indicates if ADAMTS-13 activity is at one of four level-indicator points: 0, 0.1, 0.4, or 0.8 IU/mL. Results Screen results were interpreted as binary data in that ADAMTS-13 activity was above or below the 0.1 IU/mL TTP clinical threshold. Combining all sites' data, the screen exhibited 88.7% sensitivity, 90.4% specificity, 74.6% positive predictive value, and 96.2% negative predictive value, comparable to published data for quantitative assays. Five samples with quantitative results below the threshold gave screen readings of 0.1 IU/mL and seven marginally above the threshold gave screen readings of zero. All would warrant plasma exchange while the level is quantified. Nine samples with normal/near normal results gave screens of zero and confirmatory quantifications would prompt early treatment withdrawal, as is current practice. One sample generated screen/quantitative results of 0.4/0.00 IU/mL respectively and was the only clear false-negative. Conclusions The screening test provides more rapid ADAMTS-13 level evaluation than most currently available assays. Its simple operation renders it suitable for adoption in routine or specialist laboratory environments.
引用
收藏
页码:1686 / 1694
页数:9
相关论文
共 35 条
[1]  
[Anonymous], 2008, EP12A2 CLSI
[2]   Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20% [J].
Ayanambakkam, Adanma ;
Hovinga, Johanna A. Kremer ;
Vesely, Sara K. ;
George, James N. .
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (11) :E644-E646
[3]   Use of the ADAMTS13 Activity Assay Improved the Accuracy and Efficiency of the Diagnosis and Treatment of Suspected Acquired Thrombotic Thrombocytopenic Purpura [J].
Barrows, Brad D. ;
Teruya, Jun .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2014, 138 (04) :546-549
[4]   Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study [J].
Bendapudi, Pavan K. ;
Hurwitz, Shelley ;
Fry, Ashley ;
Marques, Marisa B. ;
Waldo, Stephen W. ;
Li, Ang ;
Sun, Lova ;
Upadhyay, Vivek ;
Hamdan, Ayad ;
Brunner, Andrew M. ;
Gansner, John M. ;
Viswanathan, Srinivas ;
Kaufman, Richard M. ;
Uhl, Lynne ;
Stowell, Christopher P. ;
Dzik, Walter H. ;
Makar, Robert S. .
LANCET HAEMATOLOGY, 2017, 4 (04) :E157-E164
[5]   Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura [J].
Connell, Nathan T. ;
Cheves, Tracey ;
Sweeney, Joseph D. .
TRANSFUSION, 2016, 56 (02) :354-359
[6]   Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine [J].
Coppo, Paul ;
Cuker, Adam ;
George, James N. .
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2019, 3 (01) :26-37
[7]   Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience [J].
Coppo, Paul ;
Schwarzinger, Michael ;
Buffet, Marc ;
Wynckel, Alain ;
Clabault, Karine ;
Presne, Claire ;
Poullin, Pascale ;
Malot, Sandrine ;
Vanhille, Philippe ;
Azoulay, Elie ;
Galicier, Lionel ;
Lemiale, Virginie ;
Mira, Jean-Paul ;
Ridel, Christophe ;
Rondeau, Eric ;
Pourrat, Jacques ;
Girault, Stephane ;
Bordessoule, Dominique ;
Saheb, Samir ;
Ramakers, Michel ;
Hamidou, Mohamed ;
Vernant, Jean-Paul ;
Guidet, Bertrand ;
Wolf, Martine ;
Veyradier, Agnes .
PLOS ONE, 2010, 5 (04)
[8]  
ECAT Foundation, REP SURV 2019 M2
[9]   Pre-analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis [J].
Favaloro, Emmanuel J. ;
Funk, Dorothy M. ;
Lippi, Giuseppe .
LABMEDICINE, 2012, 43 (02) :54-60
[10]   Evaluation of the Fully Automated HemosIL Acustar ADAMTS13 Activity Assay [J].
Favresse, Julien ;
Lardinois, Benjamin ;
Chatelain, Bernard ;
Jacqmin, Hugues ;
Mullier, Francois .
THROMBOSIS AND HAEMOSTASIS, 2018, 118 (05) :942-944